8-K: Krystal Biotech Reports Strong Phase 1/2 Monotherapy Efficacy and Safety for Inhaled KB707 in Advanced Lung Cancers

Krystal Biotech, Inc. announced compelling efficacy and safety data from the monotherapy cohort of its Phase 1/2 clinical trial of inhaled KB707 for advanced solid tumors affecting the lungs, highlighted at the 2025 ASCO Annual Meeting.

Summary

• Krystal Biotech presented a clinical update on the monotherapy cohort from its Phase 1/2 clinical trial of inhaled KB707 for the treatment of solid tumors of the lung at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
• KB707 is a replication-defective herpes simplex virus type 1 (HSV-1)-based immunotherapy vector encoding human IL-12 and IL-2, designed for local delivery of high cytokine doses to the tumor microenvironment.
• The inhaled delivery of KB707 was safe and well tolerated, with most treatment-related adverse events (TRAEs) being Grade 1 or 2 and transient; no Grade 4 or Grade 5 TRAEs were observed.
• The maximum tolerated dose (MTD) was not reached, and the recommended Phase 2 dose is 10^9 PFU.
• In heavily pre-treated non-small cell lung cancer (NSCLC) patients, single-agent KB707 demonstrated an objective response rate (ORR) of 27% at the abstract data cut, which improved to 36% with extended follow-up (as of April 15, 2025).
• Responses were durable, with median duration of response (DOR) and progression-free survival (PFS) not yet reached.
• A 72-year-old patient with Stage 4 NSCLC (after 2 lines of prior immune checkpoint inhibitors) exhibited an ongoing partial response and resolution of target lung lesions.
• The company is currently evaluating KB707 in combination with pembrolizumab in expansion cohorts, with ongoing enrollment for patients with Stage 3 or 4 NSCLC.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical trial results for KB707, demonstrating strong efficacy (36% ORR in heavily pre-treated NSCLC) and a favorable safety profile. The durability of response and the ongoing combination therapy trials further enhance the positive outlook, addressing a significant unmet medical need.

Positives

• Inhaled KB707 demonstrated a favorable safety profile, with most treatment-related adverse events (TRAEs) being Grade 1 or 2 and transient, and no Grade 4 or 5 TRAEs reported.
• The maximum tolerated dose (MTD) was not reached, indicating a wide therapeutic window for the drug.
• Single-agent KB707 achieved a compelling objective response rate (ORR) of 36% in heavily pre-treated NSCLC patients, which is significant given their limited therapeutic options.
• The observed responses were durable, with median duration of response (DOR) and progression-free survival (PFS) not yet reached, suggesting sustained anti-tumor activity.
• The novel HSV-based vector platform allows for local delivery of high doses of cytokines (IL-12 and IL-2) to the lung tumor microenvironment, minimizing systemic toxicity.
• Early increase in IFN-γ was observed after a single dose, indicating a positive immunologic response.
• The promising combination of KB707 with anti-PD-1 (pembrolizumab) is currently under evaluation, suggesting potential for enhanced anti-tumor activity and overcoming resistance.

Future Outlook

Krystal Biotech is actively enrolling patients for expansion cohorts to evaluate inhaled KB707 in combination with pembrolizumab for Stage 3 or 4 non-small cell lung cancer, aiming to enhance anti-tumor activity and potentially overcome primary anti-PD1 resistance.

Management Comments

• Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic, presented the clinical update at ASCO.
• The company believes the delivery of cytokines via their novel vector platform suggests that KB707 may have a synergistic effect with immune checkpoint inhibitors to enhance anti-tumor activity and potentially overcome primary anti-PD1 resistance.

Industry Context

The clinical data for KB707 addresses a critical unmet need for patients with advanced non-small cell lung cancer (NSCLC) who have limited therapeutic options after failing to respond to immune checkpoint inhibitors (ICI). The local delivery mechanism and potential synergy with existing immunotherapies position KB707 as a promising new approach in a challenging disease area.

Comparison to Industry Standards

• Patients with advanced non-small cell lung cancer (NSCLC) who do not respond to immune checkpoint inhibitors (ICI) have very limited therapeutic options, highlighting the significant unmet need that KB707 aims to address.
• The 36% ORR in heavily pre-treated NSCLC patients as a monotherapy is a strong signal, especially when compared to typical response rates for third-line or later therapies in this patient population, which are often in the low single to double digits.
• The durable responses (median DOR and PFS not reached) suggest a more sustained benefit than many conventional treatments for advanced, refractory lung cancer.
• The safety profile, with most TRAEs being Grade 1 or 2 and no Grade 4/5 events, compares favorably to systemic cytokine therapies (e.g., recombinant IL-12 or IL-2) which have historically been hindered by significant systemic toxicity.

Stakeholder Impact

• Shareholders: Positive clinical data is likely to increase investor confidence and potentially lead to an increase in share price.
• Patients: Offers a promising new therapeutic option for advanced lung cancer patients, especially those who have failed prior immune checkpoint inhibitor therapies.
• Medical Community: Provides new insights into the potential of HSV-based gene therapies and local cytokine delivery for solid tumors, potentially influencing future treatment paradigms.
• Employees: Positive clinical progress can boost morale and validate ongoing research and development efforts.

Next Steps

• Continue enrollment for the combination therapy cohorts of the Phase 1/2 clinical trial, evaluating inhaled KB707 in combination with pembrolizumab for Stage 3 or 4 non-small cell lung cancer.

Key Dates

Recommendation

Keywords

Krystal Biotech, KB707, lung cancer, NSCLC, immunotherapy, gene therapy, solid tumors, ASCO, clinical trial, Phase 1/2, HSV-based, IL-12, IL-2, pembrolizumab, oncology